GlobeNewswire: OncoMed Pharmaceuticals, Inc. Contains the last 10 of 198 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T10:32:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/03/15/1755185/0/en/OncoMed-Pharmaceuticals-Declares-Special-Dividend-of-Contingent-Value-Rights.html?f=22&fvtc=4&fvtv=19690OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights2019-03-15T11:00:00Z<![CDATA[REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declared a one-time special dividend in the form of a contractual right to receive, on a pro rata basis, cash payments from OncoMed upon the actual receipt by OncoMed or its affiliates of certain contingent cash amounts in the future following the exercise by Celgene Corporation or certain of Celgene Corporation’s affiliates (together, “Celgene”) of the exclusive option granted by OncoMed to Celgene in relation to OncoMed’s etigilimab product. More specifically, if a specified approval or sales milestone is achieved or if royalties are paid by Celgene to OncoMed or its affiliates in respect of the etigilimab product (in each case, pursuant to a license agreement to be entered into by OncoMed and Celgene upon Celgene’s exercise of its exclusive option in relation to OncoMed’s etigilimab product (the “TIGIT License Agreement”)), the special dividend will entitle stockholders to receive an amount in cash equal to such holder’s pro rata portion of any cash payments made by Celgene and actually received by OncoMed or its affiliates in respect thereof, net of any tax and reasonable costs and expenses incurred by OncoMed or its affiliates in connection with such payments.]]>https://www.globenewswire.com/news-release/2019/03/07/1750098/0/en/OncoMed-Announces-Fourth-Quarter-and-Full-Year-2018-Financial-Results.html?f=22&fvtc=4&fvtv=19690OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results2019-03-07T21:00:00Z<![CDATA[REDWOOD CITY, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced fourth quarter and full year 2018 financial results.]]>https://www.globenewswire.com/news-release/2018/12/05/1662395/0/en/Proposed-Combination-of-Mereo-BioPharma-and-OncoMed-Pharmaceuticals.html?f=22&fvtc=4&fvtv=19690Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals2018-12-05T13:10:40Z<![CDATA[]]>https://www.globenewswire.com/news-release/2018/11/09/1648928/0/en/OncoMed-Announces-Early-Clinical-Data-for-anti-TIGIT-Antibody.html?f=22&fvtc=4&fvtv=19690OncoMed Announces Early Clinical Data for anti-TIGIT Antibody2018-11-09T13:00:00Z<![CDATA[Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage Solid Tumors]]>https://www.globenewswire.com/news-release/2018/11/01/1641627/0/en/OncoMed-Announces-Third-Quarter-2018-Financial-Results-and-Operational-Highlights.html?f=22&fvtc=4&fvtv=19690OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights2018-11-01T20:05:00Z<![CDATA[-Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer;]]>https://www.globenewswire.com/news-release/2018/10/22/1624640/0/en/OncoMed-Announces-Interim-Phase-1b-Results-for-Navicixizumab-and-Paclitaxel-Combination-Therapy-in-Platinum-resistant-Ovarian-Cancer.html?f=22&fvtc=4&fvtv=19690OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer2018-10-22T12:00:00Z<![CDATA[Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab]]>https://www.globenewswire.com/news-release/2018/10/20/1624333/0/en/OncoMed-Announces-Interim-Phase-1b-Results-for-Navicixizumab-and-Paclitaxel-Combination-Therapy-in-Platinum-resistant-Ovarian-Cancer.html?f=22&fvtc=4&fvtv=19690OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer2018-10-20T10:30:00Z<![CDATA[Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab]]>https://www.globenewswire.com/news-release/2018/10/09/1618450/0/en/OncoMed-Announces-Upcoming-Presentation-of-Navicixizumab-Interim-Phase-1b-Data-at-the-European-Society-of-Clinical-Oncology-Meeting.html?f=22&fvtc=4&fvtv=19690OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting2018-10-09T12:00:00Z<![CDATA[REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that interim results of its ongoing Phase 1b study of navicixizumab in combination with paclitaxel in patients with platinum-resistant ovarian cancer will be presented in a poster presentation on October 20, 2018 at the European Society for Medical Oncology meeting to be held in Munich, Germany.]]>https://www.globenewswire.com/news-release/2018/09/24/1575269/0/en/OncoMed-to-Present-at-the-Cantor-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=19690OncoMed to Present at the Cantor Global Healthcare Conference2018-09-24T20:00:00Z<![CDATA[REDWOOD CITY, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed, will present a corporate update at the 2018 Cantor Global Healthcare Conference in New York, NY on Monday, October 1, 2018 at 5:15 pm Eastern Time.]]>https://www.globenewswire.com/news-release/2018/09/24/1574920/0/en/OncoMed-Announces-Publication-of-Phase-1a-Data-of-Navicixizumab.html?f=22&fvtc=4&fvtv=19690OncoMed Announces Publication of Phase 1a Data of Navicixizumab2018-09-24T12:00:00Z<![CDATA[Objective Responses Observed in Heavily-pretreated Ovarian Cancer Patients Treated with Navicixzumab Monotherapy Objective Responses Observed in Heavily-pretreated Ovarian Cancer Patients Treated with Navicixzumab Monotherapy]]>